Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 130Brain Neoplasms 115Prostatic Neoplasms 101Neoplasm Metastasis 83Lung Neoplasms 72Carcinoma, Hepatocellular 71Pancreatic Neoplasms 67Breast Neoplasms 48Melanoma 44Carcinoma, Renal Cell 36Neoplasms 33Colorectal Neoplasms 26Squamous Cell Carcinoma of Head and Neck 25Glioblastoma 24Liver Neoplasms 20Head and Neck Neoplasms 16Small Cell Lung Carcinoma 15Sarcoma 13Glioma 12Kidney Neoplasms 11Urinary Bladder Neoplasms 9Recurrence 9Gliosarcoma 8Ovarian Neoplasms 7Adenocarcinoma of Lung 7Adenocarcinoma 7Prostate Cancer Metastatic 6Cholangiocarcinoma 6Central Nervous System Neoplasms 6Uveal Melanoma 5

Interventions

Sorafenib 2nimotuzumab 1lenvatinib 1atezolizumab 1Tirapazamine 1Radiotherapy 1Radiosurgery 1Radiofrequency Ablation 1Immune Checkpoint Inhibitors 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × HCC × Radiosurgery × Clear all
NCT06823375 2026-03-04

SBRT With Immunotherapy and Atezo-Bev in HCC With Major Portal Vein Thrombosis

Chinese University of Hong Kong

Phase 2 Recruiting
40 enrolled

HCC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡